Korean Circulation Journal

  • 제47권5호
  • /
  • Pages.543-554
  • /
  • 2017
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Current Drug Therapy in Chronic Heart Failure - the New Guidelines of the European Society of Cardiology (ESC)

  • 투고 : 2017.02.02
  • 심사 : 2017.04.13
  • 발행 : 2017.09.30
⟨ 이전 논문 다음 논문 ⟩

초록

Congestive heart failure (HF) is a morbidity that is increasing worldwide due to the aging population and improvement in (acute) care for patients with cardiovascular diseases. The prognosis for patients with HF is very poor without treatment. Furthermore, (repeated) hospitalizations for cardiac decompensation cause an increasing economic burden. Modern drugs and the consequent implementation of therapeutic recommendations have substantially improved the morbidity and mortality of HF patients. This paper provides an overview of the current pharmacological management of HF patients, based on the 2016 guidelines of the European Society of Cardiology (ESC).

키워드

참고문헌

  1. Heart Failure Society of AmericaLindenfeld J, Albert NM, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-194. https://doi.org/10.1016/j.cardfail.2010.04.004
  2. Askoxylakis V, Thieke C, Pleger ST, et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010;10:105. https://doi.org/10.1186/1471-2407-10-105
  3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975. https://doi.org/10.1002/ejhf.592
  4. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016;68:1476-88. https://doi.org/10.1016/j.jacc.2016.05.011
  5. Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455-62. https://doi.org/10.1093/eurheartj/ehv464
  6. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35. https://doi.org/10.1056/NEJM198706043162301
  7. SOLVD InvestigatorsYusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302. https://doi.org/10.1056/NEJM199108013250501
  8. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8. https://doi.org/10.1161/01.CIR.100.23.2312
  9. Maggioni AP, Anker SD, Dahlstrom U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-84. https://doi.org/10.1093/eurjhf/hft134
  10. Heart Failure: 150 Questions & Answers. 2nd ed. Neuilly-sur-Seinex: Servier; 2011.
  11. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. https://doi.org/10.1016/S0140-6736(98)11181-9
  12. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9. https://doi.org/10.1161/01.CIR.0000035653.72855.BF
  13. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302. https://doi.org/10.1001/jama.283.10.1295
  14. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. https://doi.org/10.1093/eurheartj/ehi115
  15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. https://doi.org/10.1056/NEJM199909023411001
  16. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. https://doi.org/10.1056/NEJMoa030207
  17. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21. https://doi.org/10.1056/NEJMoa1009492
  18. Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure). J Am Coll Cardiol 2013;62:1585-93. https://doi.org/10.1016/j.jacc.2013.04.086
  19. Bauersachs J. The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? Eur Heart J 2013;34:2426-8. https://doi.org/10.1093/eurheartj/eht235
  20. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85. https://doi.org/10.1016/S0140-6736(10)61198-1
  21. Bohm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013;102:11-22. https://doi.org/10.1007/s00392-012-0467-8
  22. Berliner D, Bauersachs J. Eine vielversprechende neue Behandlungsoption - verandert LCZ696 die Therapie der Herzinsuffizienz? Kompendium Herz-Kreislauf 2015;11:23-7.
  23. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. https://doi.org/10.1056/NEJMoa1409077
  24. Dec GW. LCZ696 (sacubitril/valsartan): can we predict who will benefit? J Am Coll Cardiol 2015;66:2072-4. https://doi.org/10.1016/j.jacc.2015.08.877
  25. Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 2016;9:e002560.
  26. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33. https://doi.org/10.1056/NEJM199702203360801
  27. Adams KF Jr, Butler J, Patterson JH, et al. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail 2016;18:1072-81. https://doi.org/10.1002/ejhf.584
  28. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 2013;15:551-9. https://doi.org/10.1093/eurjhf/hft010
  29. Bavendiek U, Aguirre Davila L, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J. 2017 [Epub ahead of print].
  30. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. https://doi.org/10.1056/NEJMoa1504720
  31. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 2016;37:1526-34. https://doi.org/10.1093/eurheartj/ehv728
  32. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-80. https://doi.org/10.1093/eurheartj/ehq158
  33. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48. https://doi.org/10.1056/NEJMoa0908355
  34. Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016;18:786-95. https://doi.org/10.1002/ejhf.473
  35. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45. https://doi.org/10.1016/S0140-6736(99)10365-9
  36. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12. https://doi.org/10.1161/01.CIR.103.6.904
  37. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-19. https://doi.org/10.1016/S0140-6736(07)60242-6
  38. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:26L-40L. https://doi.org/10.1016/S0002-9149(97)00846-1
  39. Metra M, Nodari S, D'Aloia A, Bontempi L, Boldi E, Cas LD. A rationale for the use of ${\beta}$-blockers as standard treatment for heart failure. Am Heart J 2000;139:511-21.
  40. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet 1998;352 Suppl 1:SI8-14. https://doi.org/10.1016/S0140-6736(98)90311-7
  41. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receptor activation and cardiac fibrosis. Clin Sci (Lond) 2007;112:467-75. https://doi.org/10.1042/CS20060275
  42. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015;65:257-63. https://doi.org/10.1161/HYPERTENSIONAHA.114.04488

피인용 문헌

  1. Analysis of microRNA Expression Profiles Induced by Yiqifumai Injection in Rats with Chronic Heart Failure vol.9, pp.None, 2018, https://doi.org/10.3389/fphys.2018.00048
  2. Device therapy in heart failure with reduced ejection fraction-cardiac resynchronization therapy and more vol.43, pp.5, 2017, https://doi.org/10.1007/s00059-018-4710-6
  3. Current drug therapy for heart failure with reduced ejection fraction vol.43, pp.5, 2018, https://doi.org/10.1007/s00059-018-4712-4
  4. Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure vol.10, pp.8, 2017, https://doi.org/10.3390/nu10081120
  5. The Physiology and Pathophysiology of T-Tubules in the Heart vol.12, pp.None, 2017, https://doi.org/10.3389/fphys.2021.718404
  6. ADAM17, A Key Player of Cardiac Inflammation and Fibrosis in Heart Failure Development During Chronic Catecholamine Stress vol.9, pp.None, 2017, https://doi.org/10.3389/fcell.2021.732952
  7. Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment vol.51, pp.5, 2017, https://doi.org/10.4070/kcj.2021.0070